La Jolla Pharma autoimmune news

La Jolla will seek options other than liquidation after failing three times to convene enough shareholders to vote on the liquidation proposal. The company said that about 92% of shareholders did not return a proxy card or otherwise indicate their vote on plans to liquidate and dissolve the biotech, which were announced in October (see BioCentury, Oct. 19. ...